Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Yorke
    Yorke
  10. Wu
    Wu

Groups

  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2122)
  6. GSK Faculty (1936)
  7. Center for Hematologic Malignancies (1671)
  8. Hematologic Malignancies, Division of (1608)
  9. Gynecology Disease Management Team (1426)
  10. Sloan Kettering Institute Faculty (1398)
Search Within
Formats
  1. Journal Article (7381)
  2. Meeting Abstract (4692)
  3. Review (615)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4608)
  2. Surgery (3547)
  3. Survivorship Research (2657)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2122)
  6. GSK Faculty (1936)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (243)
  2. 2024 (783)
  3. 2023 (760)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2611)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (525)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13846)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hematologic malignancies
    Book Section

    Gupta, M.; Latcha, S.
    In Finkel, K. W.; Perazella, M. A.; Cohen, E. P. (Eds.) Onco-Nephrology (2020)

    Fulltext@MSK | Save
  • The development and implementation of a gynecologic cancer survivorship tool
    Meeting Abstract

    Carter, J.; Abu-Rustum, N.; Saban, S.; Chen, L.; Vickers, A.; Billanti, G.; Connors, N.; Broach, V.; Brown, C.; Chi, D.; more...
    Journal of Sexual Medicine (2020)

    Fulltext@MSK | Save
  • Breast cancer patients in a female sexual medicine and women's health program: A cross-sectional retrospective study
    Meeting Abstract

    Carter, J.; Saban, S.; Arkema, A.; Goldfrank, D.; Goldfarb, S.
    Journal of Sexual Medicine (2020)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agent
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Leonard, J.; Batlevi, C. L.; Gabrail, N.; Pagel, J. M.; Yang, J.; Whalen, J.; Adib, D.; Morschhauser, F.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibody (mAb) - Final primary analysis
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; BladeĢ, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics
    Meeting Abstract

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N. S.; Sborov, D. W.; Suvannasankha, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Interim analysis from the OPTIC trial - A dose-ranging study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Lomaia, E.; Turkina, A.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Rojas, C.; Chuah, C.; Arthur, C.; Apperley, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save